Isan Chen

Isan Chen has over 20 years of work experience in the medical field. In 2000, they began their career as a Physician for the City of Hope. After one year, they moved to MD Anderson Cancer Center as an Assistant Professor of GU Medical Oncology. In 2004, they joined Pfizer as the Vice President of GU Tumor Lead. In 2010, they became the Chief Medical Officer for Aragon Pharmaceuticals, Inc. In 2013, they were appointed as the Executive Vice President and Chief Medical & Development Officer of Mirati Therapeutics. In 2019, they were appointed as a Director for Tyra Biosciences. In 2020, they joined Treadwell Therapeutics, Inc. as a Director and MBrace Therapeutics, Inc. as the Chief Executive Officer.

Isan Chen completed a Hematology/Oncology Fellowship at UC San Diego from 1997 to 2000. Prior to that, they attended USP - Universidade de São Paulo from 1981 to 1986 where they studied Medicine. They have also obtained certifications in Hematology from ABIM in April 2022, Medical Oncology from ABIM in December 2021, and Internal Medicine from ABIM in 2016.